Akèy › Kolit Ulseratif › Kalifòni › San Diego
Etid klinik pou Kolit Ulseratif nan San Diego, CA
15 etid pou Kolit Ulseratif ap chèche patisipan nan sit nan ak bò kote San Diego (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Ap rekriteFaz 2
- Southern California Res. Ctr /ID# 280476, Coronado · 2 mi lwen
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ap rekriteFaz 3
- Rady Children's Hospital /ID# 271873, San Diego
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 2
- Southern California GI and Liver Centers (SCLC), Coronado · 2 mi lwen
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Ap rekriteFaz 2
- Site 023, La Jolla · 11 mi lwen
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 2
- Site US-018, San Diego
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Ap rekriteFaz 2
- Southern California Research Center ( Site 1044), Coronado · 2 mi lwen
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Ap rekriteFaz 2
- Medical Associates Research Group, Inc., San Diego
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 3
- Medical Associates Research Group, Inc., San Diego
- Southern California Research Center, Coronado · 2 mi lwen
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 3
- Southern California GI & Liver Centers - Site Number: 8400062, Coronado · 2 mi lwen
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 3
- Medical Associates Research Group, Inc., San Diego
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 3
- Clinical Applications Laboratories Inc - Site Number: 8400056, San Diego
- Medical Associates Research Group - Site Number: 8400063, San Diego
- Southern California GI & Liver Centers - Site Number: 8400062, Coronado · 2 mi lwen
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Ap rekrite
- UC San Diego Health, La Jolla · 11 mi lwen
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Ap rekriteEtid obsèvasyon
- Scripps Clinic Torrey Pines, La Jolla · 11 mi lwen
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ap rekriteFaz 3
- Rady Children's Hospital - San Diego - PIN, San Diego
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
Ap rekriteFaz 2
- University of California San Diego, La Jolla · 11 mi lwen
Etid Kolit Ulseratif nan lòt vil
- New York City, NY23 etid
- Orlando, FL22 etid
- Miami, FL21 etid
- Houston, TX17 etid
- San Antonio, TX16 etid
- Tacoma, WA15 etid
- Chicago, IL15 etid
- Tyler, TX14 etid
- Colorado Springs, CO14 etid
- Los Angeles, CA13 etid
- St. Louis, MO13 etid
- Washington, DC12 etid
Lòt etid nan San Diego
- Kansè Poumon ki pa ti selil48 etid
- Kansè nan tete41 etid
- Kansè (tout kalite)32 etid
- Kansè pwostat31 etid
- Kansè Metastatik30 etid
- Kansè kolorektal25 etid
- Kansè pankreyas24 etid
- Kansè ovè24 etid
- Kansè poumon23 etid
- Ensifizyans kadyak23 etid
- Obèsite23 etid
- Depresyon21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.